DOCSLIB.ORG

EXECUTIVE SUMMARY Steroids

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
EXECUTIVE SUMMARY Steroids EXECUTIVE SUMMARY PREFACE M/s Ratantray Pharmaceuticals Pvt. Ltd. is proposing a project for manufacturing of Vitamins, Steroids & Hormones. SITE DESCRIPTION The said project will come up at H1-174 RIICO, Shree Khatushyam Ji Industrial Area, Reengus, District-Sikar, Rajasthan. The total land available is 500 square metre. The complete land is under acquisition. PROJECTDESCRIPTION M/s Ratantray Pharmaceuticals Pvt. Ltd. is proposing a project for manufacturing of Vitamins, Steroids & Hormones. As per EIA Notification dated 14th Sept., 2006 and amended from time to time, the proposed project falls under Category “B”, Project or Activity 5(f) Synthetic organic chemical Industry. The project is submitted at SEIAA Rajasthan as the proposed project is in notified industrial area. The details of Raw materials are as shown in the table below: Table-1 List of Raw Material S. No. Raw Material Unit Quantity Standard Per Month Per Year (5.0kg batch size) (110kg/month) (Kg) 1 Cyanocobalamin Kg 5.00 100 1200 2 Methyl Iodide Kg 4.50 90 1080 3 Sodium Kg 5.50 110 1320 Borohydride 4 Chloroform Kg 98.00 1960 23520 5 Acetone Kg 60.00 1200 14400 6 Phenol Kg 25.00 500 6000 7 Methanol Kg 13.00 260 3120 The details of Raw materials are as shown in the table below: Table-2 List of Products S. No. Vitamins 1 Methylcobalamin ( Vitamin B12) 2 Hydroxocobalamin Acetate 3 Alfacalcidol (Vitamin D) 4 Ascorbic Acid (Vitamin C) 5 Calcitriol (Vitamin D3) 6 Ergocalciferol (Vitamin D2) 7 Paricalcitol (Vitamin D2) 8 Pyridoxal 5 Phosphate (Vitamin B6) Steroids 1 | Page 1 Beclomethasone dipropionat 2 Betamethansone dipropionate 3 Betamethansone sodium phosphate 4 Betamethansone Valerate 5 Dexamethasone sodium phosphate 6 Clobetasole Propionate 7 Methyl prednisolone Acetate 8 Prednisolone Acetate 9 Methyl prednisolone 10 Prednisolone Sodium Phosphate 11 Prednisolone 12 Mometasone furoate diropotionate 13 Deflazacort 14 Budesonide Hormones 1 Testosterone 2 Testosterone Cypionate 3 Testosterone Enanthate 4 Testosterone Propionate 5 Testosterone Decanoate 6 Testosterone Acetate 7 Testosterone Phenylpropionate 8 Nandrolone 9 Nandrolone Decanoate 10 Trenbolone Enanthate 11 Norethisterone 12 Norethisterone Acetate 13 Norethisterone Enanthate The manpower of the plant will be 25 which will be sourced from local population. The water requirement for the proposed project will be 1200 litres/day. The water will be supplied by RIICO water connection. The power requirement will be 40 HP. The power will be supplied from Rajasthan Rajya Vidyut Vitran Nigam Limited.Total cost of proposed project is Rs.140 lakhs. Solid Waste Generation: The details of solid waste generation and it’s disposal is as follows: Table-3 Solid waste generation Particulars Quantity Management ETP sludge 25Kg/month ETP sludge will be transfer to CETP, Seetapur, Jaipur. Municipal Solid waste 10-12kg/month Authorised recycler 2 | Page Air Pollution Mitigation Measures: Source of emission: D.G. set Air Emissions: PM, Sox, NOx Mitigation Measures: Stack of appropriate height of 30 meters will be provided to the D.G. set. Green belt is already developed in 165 square metre area which will acts like adsorbent of air pollutants. To combat fugitive emissions roads are paved and regularly swept. Water sprinklers are provided for suppression of dust. Vehicular exhaust is being maintained by providing regular maintenance and servicing of vehicles. Same will be continued for future also. Water Pollution Mitigation Measures: The plant will be based on “Zero Effluent Discharge”. Most of the water will be recycled back. Effluent from product manufacturing process will be treated in 7 KLD ETP. Treated water will be used for green belt development. ------------------- 3 | Page .
Load more

Recommended publications
  • Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals
    Journal of Clinical Medicine Review Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals Carlotta Cocchetti 1, Jiska Ristori 1, Alessia Romani 1, Mario Maggi 2 and Alessandra Daphne Fisher 1,* 1 Andrology, Women’s Endocrinology and Gender Incongruence Unit, Florence University Hospital, 50139 Florence, Italy; [email protected] (C.C); jiska.ristori@unifi.it (J.R.); [email protected] (A.R.) 2 Department of Experimental, Clinical and Biomedical Sciences, Careggi University Hospital, 50139 Florence, Italy; [email protected]fi.it * Correspondence: fi[email protected] Received: 16 April 2020; Accepted: 18 May 2020; Published: 26 May 2020 Abstract: Introduction: To date no standardized hormonal treatment protocols for non-binary transgender individuals have been described in the literature and there is a lack of data regarding their efficacy and safety. Objectives: To suggest possible treatment strategies for non-binary transgender individuals with non-standardized requests and to emphasize the importance of a personalized clinical approach. Methods: A narrative review of pertinent literature on gender-affirming hormonal treatment in transgender persons was performed using PubMed. Results: New hormonal treatment regimens outside those reported in current guidelines should be considered for non-binary transgender individuals, in order to improve psychological well-being and quality of life. In the present review we suggested the use of hormonal and non-hormonal compounds, which—based on their mechanism of action—could be used in these cases depending on clients’ requests. Conclusion: Requests for an individualized hormonal treatment in non-binary transgender individuals represent a future challenge for professionals managing transgender health care. For each case, clinicians should balance the benefits and risks of a personalized non-standardized treatment, actively involving the person in decisions regarding hormonal treatment.
    [Show full text]
  • Anabolic-Androgenic Steroids in Horses: Natural Presence and Underlying Biomechanisms
    ANABOLIC-ANDROGENIC STEROIDS IN HORSES: NATURAL PRESENCE AND UNDERLYING BIOMECHANISMS Anneleen Decloedt Dissertation submitted in the fulfilment of the requirements for the degree of Doctor of philosophy (PhD) in Veterinary Sciences, Faculty of Veterinary Medicine, Ghent University PROMOTER Prof. dr. ir. Lynn Vanhaecke Ghent University, Faculty of Veterinary Medicine Department of Veterinary Public Health and Food Safety Laboratory of Chemical Analysis MEMBERS OF THE READING COMMITTEE Prof. dr. James Scarth HFL Sport Science, Cambridgeshire, United-Kingdom Prof. dr. Peter Van Eenoo Ghent University, DoCoLab, Zwijnaarde, Belgium Prof. dr. Ann Van Soom Ghent University, Faculty of Veterinary Medicine, Merelbeke, Belgium MEMBERS OF THE EXAMINATION COMMITTEE Dr. Ludovic Bailly-Chouriberry Laboratoires des Courses Hippiques, Verrières-le-Buisson, France Dr. Leen Van Ginkel Wageningen University, RIKILT, Wageningen, The Netherlands Prof. dr. Myriam Hesta Ghent University, Faculty of Veterinary Medicine, Merelbeke, Belgium This work was funded by the Fédération Nationale des Courses Françaises (via the Laboratoire des Courses Hippiques) and executed at the Laboratory of Chemical Analysis (Faculty of Veterinary Medicine, Ghent University, Merelbeke). The author and the promoter give the authorisation to consult and to copy parts of this work for personal use only. Every other use is subject to the copyright laws. Permission to reproduce any material contained in this work should be obtained from the author. “The universe is full of magic, Just patiently waiting for our wits to grow sharper” TABLE OF CONTENTS TABLE OF CONTENTS Chapter I – General Introduction 1 1. Steroids 3 1.1 Chemical structure 1.2 (Steroid) hormones and their role in the endocrine system 1.3 Biosynthesis of steroid hormones 1.4 Anabolic-androgenic steroids (AAS) 1.5 Synthesis and absorption of the steroid precursor cholesterol 2.
    [Show full text]
  • Quick Determination of 105 Doping in Animal Derived Food By
    QTRAP®质谱系统对动物源食品中105种兴奋剂的快速分析 检测 Quick Determination of 105 Doping in Animal – derived Food by QTRAP® System 杨总1，陈丹2，程海燕1，李立军1，郭立海1 Yang Zong1，Chen Dan2，Cheng Haiyan1，Li Lijun1，Guo Lihai1 1 SCIEX亚太应用支持中心，上海； 2 湖北省武汉食品化妆品检验所 1 SCIEX Asia Pacific Application Support Center, Shanghai, China; 2 Wuhan Institute for Food and Cosmetic Control, Hubei Province, China; Keywords：doping；SCIEX QTRAP® 4500 系统； LC-MS/ MS；quantitative analysis 引言 在现代畜牧养殖业中，一些不法分子长期使用各种饲料添加 剂和人工合成激素类化合物，造成动物源食品中的药物残留，最 终成为食源性兴奋剂的来源[1]。运动员食用含有某些药物残留的食 物，可导致其兴奋剂检测呈阳性。国家反兴奋剂中心和世界反兴 奋剂机构（WADA）等组织机构明确规定了兴奋剂的违禁药物的种 SCIEX ExionLC™液相和SCIEX QTRAP® 4500质谱系统 类，主要包含了β-受体激动剂、固醇类激素、糖皮质激素、利尿 剂、玉米赤霉醇类等等。总体而言，兴奋剂的作用主要是对身体或 者中枢神经系统起到选择性的作用，能促进肌肉组织快速增长、增 4. 建立好了105种兴奋剂EPI二级谱库，软件自动进行匹配二级质 强机体活力和敏捷度，还可使运动员疲劳减轻，自信心增强，注意 谱图，保证筛查结果准确可靠； 力集中[2]。因此在体育赛事过程中，为了保证赛事结果的公平、公 正，在运动员食品安全保障过程中，必须对食品中兴奋剂进行严格 5. 方法现成，省去开发方法的时间，提高了工作效率； 的监控。本文针对动物源食品中的常见105种兴奋剂，建立了采用 QTRAP®系统快速筛查和定量方法，该方法完全满足在体育赛事过 1. 实验方法 程中对兴奋剂监管的分析要求。 1.1 液相色谱条件 该方案的特点和优势 色谱柱：Phenomenex Kinetex 2.6µm F5 100 Å 150×3 µm 流动相：水相（水中含有5 mM乙酸铵和0.01%甲酸），有机 1. 方法覆盖面广，包含了常见五大类β-受体激动剂、固醇类激 相为乙腈，梯度洗脱 素、糖皮质激素、利尿剂、玉米赤霉醇类兴奋剂，共105种； 1.2 质谱条件 2. 本实验详细优化了前处理过程，考察了化合物的稳定性； 扫描模式：MRM-IDA-EPI，正负离子同时扫描，MRM离子对见 3. 实验采用MRM-IDA-EPI扫描实现一针进样同时定量和定性分 表1。 析，快速灵敏，满足国内外标准品的要求； RUO-MKT-02-9756-ZH-A p 1 离子源：ESI源；离子源参数：喷雾电压（IS）：5500V（+） 2. 结果与讨论 /-4500V（-）；离子源温度：600℃；气帘气（CUR）：35psi；碰 2.1 前处理过程的优化 撞气（CAD）：Medium；雾化气（GS1）：55psi；辅助雾化气 （GS2）：60psi 本实验详细优化了前处理过程，实验结果表明在动物源食品 中酸化乙腈的提取效率最高，绝大部分化合物回收率在70%以上 1.3 样品前处理过程 （见图1、图2、图3）。由于基质的复杂性，实验比较了5种不同 称取5g样品于50 mL离心管 → 加入10 mL乙酸铵缓冲溶液混 的SPE柱的净化效率，由图4可以看出，PRIME HLB 净化效果最优 异，回收率较高。 匀 → 加入β-葡萄糖醛甙酶进行酶解 → 加入酸化乙腈进行提取， 震荡混匀后加入NaCl和Mg2SO4 → 萃取之后高速离心取上清液采用 PRIME HLB进行净化 → 吹干后复溶上机测试。 100 80 60 40 20 0 酸化叔丁基甲醚 酸化乙腈 碱化乙腈 图1.
    [Show full text]
  • MMC International BV
    M.M.C. International Steroid Substances Steroid Test A Colour Steroid Test B Colour Steroid Test B Colour with UV Light Stanozolol/ Oxandrolone Test Clenbuterol/ Oxymetholone Test Ephedrine Test Alfadolone Orange Yellow Nil - - - Androsterone Orange Yellow White - - - Beclometasone Brown–yellow Orange Nil - - - Betamethasone Orange–brown Pink–Orange Nil - - - Boldenone Base (Equipoise, Ganabol) (pure powder) Warm red after 2 min. Dark Orange after 2 min. Bright Light Orange - - - Boldenone Undecanoate (oil) Dark brownish-red Dark Red Bright Light Orange - - - Boldenone Undecylenate (oil) Orange - Light Brown Dark Orange → Brown Bright Light Orange-Yellow - - - Carbenoxolone (CBX) Orange Yellow Yellow - - - Cholesterol Violet Orange White - - - Clenbuterol (Spiropent, Ventipulmin) - - - - Purple - Dark brown with yellow-green on the Dark brown with yellow-green on the Clomiphene (Androxal, Clomid, Omifin) Nil Dark brown to black No reaction Dark brown to black sides of the ampoule sides of the ampoule Cortisone Orange Yellow Green - - - Desoxycortone Blue–black Yellow Yellow - - - Dexamethasone Yellow Orange–pink Nil - - - Dienestrol Yellow Orange–red Nil - - - Diethylstilbestrol (DES) Orange (→yellow–green) Nil - - - Dimethisterone Brown–green Orange–red Yellow - - - Drostanolone Propionate (Masteron) (oil) Bright green Yellow-Orange Orange - - - Dydrogesterone (Duphaston) - Orange Green-Yellow - - - Enoxolone Orange Yellow Green-Yellow - - - Ephedrine (also for Pseudo- and Nor-Ephedrine) - - - - - Orange Estradiol (Oestradiol) Orange
    [Show full text]
  • Toiminta Unita on Ulla La Mungukurti |
    TOIMINTAUNITA USON 20180071390A1ULLA LA MUNGUKURTI | ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2018/ 0071390 A1 PATEL et al. (43 ) Pub . Date : Mar . 15 , 2018 ( 54 ) COMPOSITIONS OF PHARMACEUTICAL A61K 9 / 06 (2006 .01 ) ACTIVES CONTAINING DIETHYLENE A61K 9 /00 (2006 .01 ) GLYCOL MONOETHYL ETHER OR OTHER A61K 31 /573 ( 2006 .01 ) ALKYL DERIVATIVES A61K 31/ 565 ( 2006 .01 ) A61K 31/ 4439 ( 2006 . 01 ) ( 71 ) Applicant : THEMIS MEDICARE LIMITED , A61K 31 / 167 ( 2006 . 01 ) Mumbai (IN ) A61K 31 / 57 (2006 . 01) (52 ) U . S . CI. (72 ) Inventors : Dinesh Shantilal PATEL , Mumbai CPC .. .. .. A61K 47 / 10 ( 2013 . 01 ) ; A61K 9 /4858 ( IN ) ; Sachin Dinesh PATEL , Mumbai ( 2013 .01 ) ; A61K 9 /08 ( 2013 .01 ) ; A61K 9 / 06 ( IN ) ; Shashikant Prabhudas ( 2013 .01 ) ; A61K 9 / 0014 ( 2013 .01 ) ; A61K KURANI, Mumbai ( IN ) ; Madhavlal 31/ 573 ( 2013 .01 ) ; A61K 31 /57 ( 2013 .01 ) ; Govindlal PATEL , Mumbai ( IN ) A61K 31/ 565 ( 2013 .01 ) ; A61K 31 /4439 (73 ) Assignee : THEMIS MEDICARE LIMITED , ( 2013 .01 ) ; A61K 31/ 167 ( 2013 .01 ) ; A61K Mumbai (IN ) 9 /0048 ( 2013 .01 ) ; A61K 9 /0019 (2013 .01 ) ( 57 ) ABSTRACT (21 ) Appl. No .: 15 / 801, 390 The present invention relates to pharmaceutical composi tions of various pharmaceutical actives, especially lyophilic ( 22 ) Filed : Nov . 2 , 2017 and hydrophilic actives containing Diethylene glycol mono ethyl ether or other alkyl derivatives thereof as a primary Related U . S . Application Data vehicle and /or to pharmaceutical compositions utilizing (62 ) Division of application No. 14 /242 , 973 , filed on Apr. Diethylene glycol monoethyl ether or other alkyl derivatives 2 , 2014 , now Pat. No. 9 , 827 ,315 .
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0296.191 A1 PATEL Et Al
    US 20140296.191A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0296.191 A1 PATEL et al. (43) Pub. Date: Oct. 2, 2014 (54) COMPOSITIONS OF PHARMACEUTICAL (52) U.S. Cl. ACTIVES CONTAINING DETHYLENE CPC ............... A61K 47/10 (2013.01); A61 K9/0019 GLYCOL MONOETHYLETHER OR OTHER (2013.01); A61 K9/0048 (2013.01); A61 K ALKYL DERVATIVES 45/06 (2013.01) USPC ........... 514/167: 514/177; 514/178: 514/450; (71) Applicant: THEMIS MEDICARE LIMITED, 514/334: 514/226.5: 514/449; 514/338; Mumbai (IN) 514/256; 514/570; 514/179; 514/174: 514/533; (72) Inventors: Dinesh Shantilal PATEL, Mumbai (IN); 514/629; 514/619 Sachin Dinesh PATEL, Mumbai (IN); Shashikant Prabhudas KURANI, Mumbai (IN); Madhavlal Govindlal (57) ABSTRACT PATEL, Mumbai (IN) (73) Assignee: THEMIS MEDICARE LIMITED, The present invention relates to pharmaceutical compositions Mumbai (IN) of various pharmaceutical actives, especially lyophilic and hydrophilic actives containing Diethylene glycol monoethyl (21) Appl. No.: 14/242,973 ether or other alkyl derivatives thereofas a primary vehicle and/or to pharmaceutical compositions utilizing Diethylene (22) Filed: Apr. 2, 2014 glycol monoethyl ether or other alkyl derivatives thereofas a primary vehicle or as a solvent system in preparation of Such (30) Foreign Application Priority Data pharmaceutical compositions. The pharmaceutical composi Apr. 2, 2013 (IN) ......................... 1287/MUMA2013 tions of the present invention are safe, non-toxic, exhibits enhanced physical stability compared to conventional formu Publication Classification lations containing such pharmaceutical actives and are Suit able for use as injectables for intravenous and intramuscular (51) Int. Cl. administration, as well as for use as a preformed solution/ A647/ (2006.01) liquid for filling in and preparation of capsules, tablets, nasal A6 IK 45/06 (2006.01) sprays, gargles, dermal applications, gels, topicals, liquid oral A6 IK9/00 (2006.01) dosage forms and other dosage forms.
    [Show full text]
  • Steroid Abuse by School Age Children
    epartment .D of .S Ju U s t ic U.S. Department of Justice e . n o i Drug Enforcement Administration t a r t is D in Office of Diversion Control r m ug d E t A nforcemen www.dea.gov www.DEAdiversion.usdoj.gov epartment .D of .S Ju U s t ic e . n o i t a r t is D in r m ug d E t A nforcemen Office of Diversion Control www.dea.gov STEROID ABUSE BY SCHOOL AGE CHILDREN nce viewed as a problem strictly associated with body builders, Ofitness “buffs,” and professional athletes, abuse of anabolic steroids by school age children has significantly increased over the past decade. The National Institute on Drug Abuse (NIDA) estimates that more than a half million 8th and 10th grade students are now using these dangerous drugs, and increasing numbers of high school seniors do not believe steroids are risky. Students are acquiring and taking anabolic steroids without any knowledge of the dangers associated with steroid abuse. The short- term adverse physical effects of anabolic steroid abuse are fairly well known. However, the long-term adverse physical effects of anabolic steroid abuse have not been studied, and as such, are not known. In addition, this type of abuse may result in harmful side-effects as well as serious injury and death. The abuser in most cases is unaware of these hidden dangers. Presented as a public service by: This guide will help you understand why steroids are being misused, Drug Enforcement Administration and how you can provide counseling and implement procedures to Office of Diversion Control educate our youth about the dangers of these drugs.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2008/0063698 A1 Hartwig (43) Pub
    US 2008 OO63698A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0063698 A1 Hartwig (43) Pub. Date: Mar. 13, 2008 (54) CRYSTALLIZATION INHIBITION OF DRUGS now abandoned, which is a continuation of applica IN TRANSIDERMAL DRUG DELIVERY tion No. 10/010,342, filed on Dec. 5, 2001, now SYSTEMIS AND METHODS OF USE abandoned. (75) Inventor: Rod Lawson Hartwig, Plantation, FL (60) Provisional application No. 60/251.294, filed on Dec. (US) 5, 2000. Correspondence Address: Publication Classification Noven Pharmaceuticals, Inc. Jay G. Kolman, Esq. (51) Int. Cl. 11960 S.W. 144 Street A6II 3/56 (2006.01) A6F 3/00 (2006.01) Miami, FL 33186 (US) A6IP 43/00 (2006.01) (73) Assignee: NOVEN PHARMACEUTICALS, A6F 3/02 (2006.01) INC. (52) U.S. Cl. ........................... 424/448; 424/449; 514/170 (57) ABSTRACT Appl. No.: 11/897,189 (21) The invention relates to compositions and methods for (22) Filed: Aug. 29, 2007 making a transdermal drug delivery system capable of achieving substantially zero-order kinetics for delivery of Related U.S. Application Data the active agent over a period of time in excess of 24 hours and at least 72 hours, comprising a pharmaceutically accept (63) Continuation of application No. 10/751,152, filed on able active agent carrier and a rosin ester which provides a Jan. 2, 2004, now abandoned, which is a continuation crystal inhibiting and drug stabilizing effect on the active of application No. 10/353,624, filed on Jan. 29, 2003, agents incorporated therein. 13 2 2 Patent Application Publication Mar.
    [Show full text]
  • SEAC) Held on 01/10/2019 at Committee Room, Gujarat Pollution Control Board, Sector 10A,Gandhinagar
    Minutes of the 554 th meeting ofthe State Level Expert Appraisal Committee (SEAC) held on 01/10/2019 at Committee Room, Gujarat Pollution Control Board, Sector 10A,Gandhinagar. The 554 th meeting of the State Level Expert Appraisal Committee (SEAC) was held on 1st October 2019 at Committee Room, Gujarat Pollution Control Board, Sector 10A, Gandhinagar. Following members attended the meeting: 1. Dr. Dinesh Misra, Chairman, SEAC 2. Shri S. C. Srivastav, Vice Chairman, SEAC 3. Shri Rajesh. I. Shah, Member, SEAC 4. Shri V. N. Patel, Member, SEAC 5. Dr. V. K. Jain, Member, SEAC 6. Shri A. K. Mule, Member, SEAC The regular agenda of Appraisal, Screening & Scoping/ToR, Reconsideration cases were taken up. The Committee considered the applications made by project proponents, additional details submitted as required by the SEAC/SEIAA and details furnished in the Form-1, PFR, EIA-EMP reports. Proposal No. Name and Address of the Unit Remarks 04 SIA/GJ/IND2/29059/2017 M/s. Dev Dyechem Industries EC – Plot No. C-1/324, Phase-I & II GIDC – Reconsideration Naroda, Ahmedabad. • PP remained absent in the EC – Appraisal presentation held on 01/10/2019. • After detailed discussion, Committee decided to defer the proposal and consider the same in one of the upcoming meeting of SEAC. 05 SIA/GJ/IND2/29678/2018 M/s. Apex Pharma EC – C-298/2/4, Saykha Industrial Estate, Reconsideration Saykha, Ta- Vagra, Dist -Bharuch. Category of the unit: 5(f) Project status: New • Project proponent (PP) submitted online application vide no. SIA/GJ/IND2/29678/2018 dated 30/04/19 for obtaining Environmental Clearance.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,284,263 B1 Place (45) Date of Patent: Sep
    USOO6284263B1 (12) United States Patent (10) Patent No.: US 6,284,263 B1 Place (45) Date of Patent: Sep. 4, 2001 (54) BUCCAL DRUG ADMINISTRATION IN THE 4,755,386 7/1988 Hsiao et al. TREATMENT OF FEMALE SEXUAL 4,764,378 8/1988 Keith et al.. DYSFUNCTION 4,877,774 10/1989 Pitha et al.. 5,135,752 8/1992 Snipes. 5,190,967 3/1993 Riley. (76) Inventor: Virgil A. Place, P.O. Box 44555-10 5,346,701 9/1994 Heiber et al. Ala Kahua, Kawaihae, HI (US) 96743 5,516,523 5/1996 Heiber et al. 5,543,154 8/1996 Rork et al. ........................ 424/133.1 (*) Notice: Subject to any disclaimer, the term of this 5,639,743 6/1997 Kaswan et al. patent is extended or adjusted under 35 6,180,682 1/2001 Place. U.S.C. 154(b) by 0 days. * cited by examiner (21) Appl. No.: 09/626,772 Primary Examiner Thurman K. Page ASSistant Examiner-Rachel M. Bennett (22) Filed: Jul. 27, 2000 (74) Attorney, Agent, or Firm-Dianne E. Reed; Reed & Related U.S. Application Data ASSciates (62) Division of application No. 09/237,713, filed on Jan. 26, (57) ABSTRACT 1999, now Pat. No. 6,117,446. A buccal dosage unit is provided for administering a com (51) Int. Cl. ............................. A61F 13/02; A61 K9/20; bination of Steroidal active agents to a female individual. A61K 47/30 The novel buccal drug delivery Systems may be used in (52) U.S. Cl. .......................... 424/435; 424/434; 424/464; female hormone replacement therapy, in female 514/772.3 contraception, to treat female Sexual dysfunction, and to treat or prevent a variety of conditions and disorders which (58) Field of Search ....................................
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Control Be Implemented. the First Large-Scale Systematic Olympic Games
    Br J Sports Med: first published as 10.1136/bjsm.11.4.162 on 1 December 1977. Downloaded from 162 Brit. J. Sports Med. - Vol. 1 1, No. 4, December 1977, pp. 162-169 RADIOIMMUNOASSAY OF ANABOLIC STEROIDS: AN EVALUATION OF THREE ANTISERA FOR THE DETECTION OF ANABOLIC STEROIDS IN BIOLOGICAL FLUIDS Robert DUGAL, Ph.D., Claire DUPUIS, Ph.D. and Michel J. BERTRAND, Ph.D. Centre de Recherches en Sciences de la Sante, Institut National de la Recherche Scientifique, Centre Hospitalier Louis-H. Lafontaine, Montrdal, Quebec, Canada ABSTRACT Recently developped radioimmunoassays (RIA) for the analysis of anabolic steroids and their metabolites in biological fluids were tested for cross-reactivity with other types of steroids. Results show that the degree of desirable cross-reactivity within the two classes of orally active anabolic steroids vary widely and that the antiserum for 19-Nortestosterone (the active principle of intramuscular, preparations) has a very high degree of undesirable cross- reactivity with components of oral contraceptives. Single and multiple dose studies in human volunteers demonstrate that the detection level and degree of retrospectivity are likewise variable but that the test easily detects most anabolic steroids during treatment. At the present time, the combination of the three antisera for the assay of a sample appears to be a relatively rapid and economic method for screening large numbers of samples in situations where doping control of anabolic steroids is required. The importance of utilizing physico-chemical means for identification of RIA potential positives is emphasized. INTRODUCTION (Sumner, 1974: Brooks et al, 1975) and identification procedures for a limited number of them have also been copyright.
    [Show full text]